We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Artemis Therapeutics Inc (PK) | USOTC:ATMS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.498 | 0.181 | 0.50 | 0.00 | 01:00:00 |
DELAWARE
|
84-1417774
|
(State or other jurisdiction of
|
(I.R.S. Employer Identification No.)
|
incorporation or organization)
|
|
18 East 16th Street, Suite 307, New York, NY
|
10003
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
ATMS
|
OTCQB
|
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☐
|
|
|
|
PAGE
|
|
|
|
4
|
||
|
|
|
4
|
||
|
|
|
|
5
|
|
|
|
|
|
6
|
|
|
|
|
|
7
|
|
|
|
|
|
8
|
|
|
|
|
|
9 | |
|
|
|
18
|
||
|
|
|
20
|
||
|
|
|
21 | ||
|
|
|
21
|
||
|
|
|
22
|
|
PAGE
|
|
|
5
|
|
|
|
6
|
|
|
|
7 | |
|
|
8 | |
|
|
9-17
|
|
As of
March 31, |
As of
December 31,
|
||||||||||
|
Note
|
2021
(Unaudited)
|
2020
(Audited)
|
|||||||||
|
||||||||||||
ASSETS
|
||||||||||||
|
||||||||||||
Current assets
|
||||||||||||
Cash and cash equivalents
|
2
|
1
|
||||||||||
Other accounts receivable and prepaid expenses
|
3
|
10
|
||||||||||
Total current assets
|
5
|
11
|
||||||||||
|
||||||||||||
TOTAL ASSETS
|
5
|
11
|
||||||||||
|
||||||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||||||
|
||||||||||||
Current liabilities
|
||||||||||||
Accrued expenses and other payables
|
265
|
246
|
||||||||||
Related Parties
|
8
|
117
|
110
|
|||||||||
Total current liabilities
|
382
|
356
|
||||||||||
|
||||||||||||
Total Liabilities
|
382
|
356
|
||||||||||
|
||||||||||||
Shareholders’ equity
|
||||||||||||
Series A Convertible Preferred stock, $0.01 par value - Authorized: 10,000,000 shares; issued and outstanding: 453 shares as of March 31, 2021 and December 31, 2020
|
(*
|
)
|
(*
|
)
|
||||||||
Series C Convertible Preferred stock, $0.01 par value - Authorized: 250 shares; issued and outstanding: 250 shares as of March 31, 2021 and December 31, 2020
|
(*
|
)
|
(*
|
)
|
||||||||
Common stock, $0.01 par value - authorized: 51,000,000; issued and outstanding: 5,153,461 as of March 31, 2021 and December 31, 2020
|
52
|
52
|
||||||||||
Additional paid in capital
|
7
|
1,925
|
1,921
|
|||||||||
Accumulated deficit
|
(2, 354
|
)
|
(2,318
|
)
|
||||||||
Total stockholders' equity
|
(377
|
)
|
(345
|
)
|
||||||||
|
||||||||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
5
|
11
|
|
Three Months Ended
March 31,
|
|||||||||||
|
2021
|
2020
|
||||||||||
|
Note
|
(Unaudited)
|
||||||||||
|
||||||||||||
General and administrative expense
|
35
|
19
|
||||||||||
|
||||||||||||
Operating loss
|
35
|
19
|
||||||||||
Finance expense
|
1
|
2
|
||||||||||
Net loss
|
36
|
21
|
||||||||||
|
||||||||||||
Net loss per share, basic and diluted
|
6
|
0.006
|
0.003
|
|||||||||
|
||||||||||||
Weighted average number of common stock used in calculation of net loss per share:
|
||||||||||||
Basic and diluted
|
5,153,461
|
5,153,461
|
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Accumulated
deficiency
|
Total
stockholders'
Equity
|
||||||||||||||||||||||||||||||
|
Number
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2020
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,921
|
(2,318
|
)
|
(345
|
)
|
|||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Share based compensation
|
-
|
-
|
-
|
-
|
-
|
-
|
4
|
-
|
4
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(36
|
)
|
(36
|
)
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Balance as of March 31, 2021
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,925
|
(2,354
|
)
|
(377
|
)
|
|
Common Stock
|
Preferred Stock A
|
Preferred Stock C
|
Additional
paid-in Capital
|
Accumulated
deficiency
|
Total
stockholders'
Equity
|
||||||||||||||||||||||||||||||
|
Number
|
USD
|
Number
|
Amount
|
Number
|
Amount
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2019
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,907
|
(2,197
|
)
|
(238
|
)
|
|||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Share based compensation
|
4
|
4
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Net loss
|
(21
|
)
|
(21
|
)
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
Balance as of March 31, 2020
|
5,153,461
|
52
|
453
|
(*
|
)
|
250
|
(*
|
)
|
1,911
|
(2,218
|
)
|
(255
|
)
|
|
Three Months Ended
March 31, |
|||||||
|
2021
|
2020
|
||||||
|
||||||||
Net cash used in operating activities
|
||||||||
Net loss
|
(36
|
)
|
(21
|
)
|
||||
|
||||||||
Share based compensation expenses
|
4
|
4
|
||||||
Decrease in other accounts receivable and prepaid expenses
|
7
|
9
|
||||||
Increase in accrued expenses and other payables
|
19
|
6
|
||||||
Increase in related parties liabilities
|
7
|
-
|
||||||
Net cash used in operating activities
|
1
|
(2
|
)
|
|||||
|
||||||||
Cash flows from financing activities
|
||||||||
Related party loan
|
-
|
2
|
||||||
|
||||||||
Increase in cash and cash equivalents
|
1
|
0
|
||||||
Cash and cash equivalents at the beginning of the period
|
1
|
2
|
||||||
|
||||||||
Cash and cash equivalents at the end of the period
|
2
|
2
|
|
As of
March 31, 2021
|
As of
December 31,
2020
|
||||||
|
||||||||
Deferred tax assets:
|
||||||||
Deferred taxes due to carryforward losses
|
2,914
|
2,906
|
||||||
|
||||||||
Valuation allowance
|
(2,914
|
)
|
(2,906
|
)
|
||||
|
||||||||
Net deferred tax asset
|
-
|
-
|
|
As of
March 31, 2021
|
As of
December 31,
2020
|
||||||
Israel
|
4,985
|
4,974
|
||||||
United States (*)
|
8,418
|
8,392
|
||||||
|
||||||||
|
13,403
|
13,366
|
Issuance
date |
|
Number of warrants outstanding as of March 31, 2021
|
|
Exercise
price |
|
Exercisable
through |
||
|
|
|
|
|
|
|
||
October 2017
|
|
|
275,000
|
|
$
|
2.00
|
|
October 2022
|
|
For the Three months ended
March 31, 2021
|
|||||||||||
|
Number of stock options
|
Weighted average exercise price
|
Aggregate intrinsic value
|
|||||||||
|
||||||||||||
Outstanding at beginning of period
|
141,528
|
0.47
|
21,051
|
|||||||||
Granted
|
-
|
-
|
-
|
|||||||||
Exercised
|
-
|
-
|
-
|
|||||||||
Cancelled
|
-
|
-
|
-
|
|||||||||
|
||||||||||||
Outstanding at end of period
|
141,528
|
0.47
|
28,008
|
|||||||||
Options exercisable at period end
|
131,111
|
0.40
|
28,008
|
Exercise price
|
|
|
Stock options outstanding as of March 31,
|
|
|
Stock options outstanding as of December 31,
|
|
|
Weighted average remaining contractual life – years as of March 31,
|
|
|
Weighted average remaining contractual life – years as of December 31,
|
|
|
Stock options exercisable as of March 31,
|
|
|
Stock options exercisable as of December 31,
|
|
|||||||
$
|
|
|
2021
|
|
|
|
2020
|
|
|
|
2021
|
|
|
|
2020
|
|
|
|
2020
|
|
|
|
2020
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.01
|
|
|
|
91,528
|
|
|
|
91,528
|
|
|
|
5.40
|
|
|
|
5.64
|
|
|
|
91,528
|
|
|
|
91,528
|
|
|
1.30
|
|
|
|
50,000
|
|
|
|
50,000
|
|
|
|
6.96
|
|
|
|
7.21
|
|
|
|
39,583
|
|
|
|
36,458
|
|
|
0.83
|
|
|
|
141,528
|
|
|
|
141,528
|
|
|
|
5.92
|
|
|
|
6.17
|
|
|
|
131,11
|
|
|
|
127,986
|
|
EXHIBIT
NUMBER
|
|
DESCRIPTION
|
|
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
101.1
|
|
The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 formatted in XBRL (eXtensible Business Reporting Language): (i) the Interim Condensed Consolidated
Balance Sheets, (ii) the Interim Condensed Consolidated Statements of Comprehensive Loss, (iii) the Condensed Consolidated Statements of Shareholders Equity, (iv) the Interim Condensed Consolidated Statements of Cash Flows and (v) related
notes to these financial statements, tagged as blocks of text and in detail.*
|
|
|
|
|
|
ARTEMIS THERAPEUTICS, INC.
|
|
|
|
|
|
|
Dated: May 13, 2021
|
By:
|
/s/ Chanan Morris
|
|
|
|
Chanan Morris
|
|
|
|
Chief Financial Officer
|
|
|
|
(Principal Executive Officer and Principal Financial and Accounting Officer)
|
|
1 Year Artemis Therapeutics (PK) Chart |
1 Month Artemis Therapeutics (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions